Clinical Trials Logo

Crohn Disease clinical trials

View clinical trials related to Crohn Disease.

Filter by:

NCT ID: NCT02010762 Completed - Crohn's Disease Clinical Trials

The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease

DETECT
Start date: February 2013
Phase: Phase 4
Study type: Interventional

The majority of patients with Crohn's disease (CD) need to undergo surgical bowel resection. Postoperative recurrence of the disease is virtually inevitable and continues to be one of the most challenging therapeutic problems in inflammatory bowel diseases. Medical treatments to prevent recurrence have had limited effect. Anti-tumor necrosis factor (TNF) agents appear promising but are hampered by immunogenicity, side effects and high cost. Vitamin D has recently received a lot of scientific attention and was found to have strong anti-inflammatory and antifibrotic effects in gut and liver inflammation. Many CD patients appear to have deficiency in Vitamin D. A controlled trial to prevent relapse of CD in medical (not surgical) remission suggested a preventive effect for Vitamin D but marginally missed its endpoint because of lack of power. The ultimate proof of the anti-inflammatory effect of Vitamin D in CD can best be studied in the prevention of postoperative recurrence.

NCT ID: NCT01991314 Completed - Ulcerative Colitis Clinical Trials

Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate

Start date: December 2011
Phase: Phase 4
Study type: Interventional

Iron deficiency anaemia is common in inflammatory bowel disease (IBD), affecting at least 20% patients at any one time. Hepcidin, a recently described anti-microbial peptide synthesized by the liver, is a key regulator of iron homeostasis. It interferes with absorption of iron into enterocytes, macrophages and hepatocytes by binding to ferroportin. Hepcidin levels rise when total body iron levels rise and protect against iron overload; conversely, in iron deficiency, levels are low. Hepcidin levels also rise under the influence of interleukins (IL)-6 and -1, a factor likely to contribute to iron deficient erythropoesis in active IBD. Whether hepcidin levels predict resistance to oral iron therapy in IBD is unknown, though it may impair its immediate oral absorption. Adult IBD patients who are anaemic report quality of life and fatigue scores comparable to those seen in malignancy. IBD diagnosed in adolescence interferes with growth, education and employment as well as psychosocial and sexual development. Not surprisingly, adolescents with IBD have a high prevalence of psychological distress, particular depression. Limited historical, and our own data suggest that children and adolescents with IBD are more anaemic than adults, and less often treated with oral iron. What is not clear is whether the apparent under-utilisation of oral iron in paediatric care is because of a perceived lack of benefit or doctors' concerns about possible side effects including worsening disease activity. To address these questions, the investigators propose a comparative study of 6 weeks of oral iron supplementation in adolescents and adults with iron deficiency anaemia in IBD. Patients will be given oral iron supplementation. Before and after iron therapy, the investigators shall assess haemoglobin concentrations; IBD activity; quality of life (QOL), perceived stress, mood and fatigue; iron metabolism, including serum hepcidin.

NCT ID: NCT01990716 Completed - Crohn Disease Clinical Trials

Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases

MICILIP
Start date: February 2013
Phase: N/A
Study type: Interventional

We will quantify one of the lipid compounds (5,6 epoxy eicosatrienoic acid (5,6 EET), 5,6- EpoxyEicosaTrienoic acid) in colonic biopsies of Inflammatory Bowel Disease patients. We will evaluate its possible use as a pathological activity biomarker and its potential as a therapeutic target. We hypothesized that 5,6-EET is present in human colonic tissues in varying quantities depending on the pathological state of the IBD patient.

NCT ID: NCT01988506 Completed - Clinical trials for Rheumatoid Arthritis

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

TRANSREG
Start date: January 6, 2014
Phase: Phase 2
Study type: Interventional

TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be performed. Extensive biological- and immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct processes responsible for the breakdown of immunological tolerance in these pathologies and (ii) to discover potential biomarkers of the IL2 response.

NCT ID: NCT01966744 Completed - Ulcerative Colitis Clinical Trials

Self-Management Assistance for Recommended Treatment (SMART) Portal

SMART
Start date: July 2013
Phase: N/A
Study type: Observational

The purpose of the study is to develop, evaluate, and optimize an interactive website (the SMART portal). The SMART portal will use IBD-specific and general assessments and interventions to reduce the burden of common barriers to treatment adherence and enhance self-management skills. This study aims to build and revise the SMART portal according to feedback and testing from participants.

NCT ID: NCT01959087 Completed - Crohn's Disease Clinical Trials

Single Port Colic Laparoscopic Surgery

TRUE
Start date: January 27, 2014
Phase: N/A
Study type: Interventional

This study aims to compare the results of colonic surgery performed by single and multiport laparoscopy.

NCT ID: NCT01958827 Completed - Crohn's Disease Clinical Trials

A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

Start date: September 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in Japanese subjects with Crohn's Disease.

NCT ID: NCT01957423 Completed - Crohn's Disease Clinical Trials

Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.

Start date: March 2012
Phase: N/A
Study type: Interventional

The objective of this study was to evaluate the effect of Whey Protein (WP) and Soy Protein (SP) nutritional supplements on nutritional status and disease activity in Crohn's disease patients.

NCT ID: NCT01951326 Completed - Crohn's Disease Clinical Trials

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

MAPUS
Start date: September 2013
Phase: Phase 3
Study type: Interventional

The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.

NCT ID: NCT01947010 Completed - Crohns Disease Clinical Trials

Pneumococcal Vaccination of Crohn Patients

PneuVAC
Start date: July 2013
Phase: Phase 4
Study type: Interventional

Inflammatory bowel disease (IBD) are at increased risk of infections. This increased susceptibility to infections is due to the disease itself, but also be-cause many patients with autoimmune conditions are treated with immuno-suppressive drugs, such as azathioprine and or TNF-a inhibitors. Streptococcus pneumoniae (pneumococcus) is a cause of worldwide morbidity and mortality and one of the most common cause of bacterial meningitis in adults. Infection with pneumococcus can be prevented with vaccination. Two pneumococcal vaccine are used in Denmark, the 23 valent polysaccharide-based vaccine (23PPV) and the 13 valent of conjugate pneumococcal vaccines (PCV13). In this study the investigators wish to study the effect of pneumococcal vaccination with either PPV23 or PCV13 in IBD patients treated with either TNF-a inhibitors, azathioprine or untreated.